In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...

Novo Nordisk is also currently awaiting a decision from the FDA, having previously applied for approval of its Wegovy weight-loss pill. As part of the U.S. pricing deal with the administration earlier ...

And one of them is pharmaceutical giant Pfizer (NYSE: PFE). Now, with a major step along the path to entering this ...

Investors in Danish pharmaceutical leader Novo Nordisk experienced significant market volatility this week following ...

Inflammatory bowel disease (IBD) has expanded beyond its initial confines of early industrialised countries in North America, Europe, and Oceania and now constitutes a global illness. Once rare in the ...

In a groundbreaking class action, Wisner Baum LLP is invoking the civil RICO statute to hold Takeda and Eli Lilly accountable for allegedly concealing the cancer risks of diabetes drug Actos. The case ...

Some studies have found that about half of people who start taking a GLP-1 drug for weight loss stop taking it within a ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

Novo Nordisk’s amycretin showed no weight-loss plateau over 36 weeks in patients with type 2 diabetes, suggesting its ...

Bernstein just threw fresh fuel on Eli Lilly's (LLY) never-ending rally, as the firm lifted its price target on the stock to ...